Year in diabetes 2012: The diabetes tsunami

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4293-4301

  Sherwin, Robert ^a   Jastreboff, A M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; BIOLOGICAL MARKER; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; IRISIN; MAGNETIC NANOPARTICLE; METFORMIN; PEPTIDE HORMONE; PLACEBO; ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA; TEPLIZUMAB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; B LYMPHOCYTE; BARIATRIC SURGERY; BRAIN; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DYSGLYCEMIA; DYSLIPIDEMIA; DYSURIA; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); POLYURIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT GAIN;

ALGORITHMS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; ENDOCRINOLOGY; HUMANS; MODELS, BIOLOGICAL; PATIENT-CENTERED CARE; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; SOCIETIES, MEDICAL; TSUNAMIS;

EID: 84870765997     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3487     Document Type: Review

References (39)

1. Centers for Disease Control and Prevention 2011 National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention
2. World Health Organization 2011 World Health Organization: diabetes fact sheet. http://www.who.int/mediacentre/factsheets/fs312/en/index.html
3. American Diabetes Association 2008 Economic costs of diabetes in the U.S. in 2007. Diabetes Care [Erratum (2008) 31:1271] 31:596-615
4. Centers for Disease Control and Prevention 2012 Diabetes data and trends. Data from the National Health Interview Survey. Statistical analysis by the Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, DivisionofDiabetesTranslation. http://www.cdc.gov/diabetes/statistics/prev/national/figage.htm
5. May AL, Kuklina EV, Yoon PW 2012 Prevalence of cardiovascular disease risk factors among US adolescents, 1999-2008. Pediatrics 129:1035-1041
6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR 2012 Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364-1379
7. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR 2012 Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577-1596
8. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S 2011 Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 154:602-613
9. Amylin Pharmaceuticals 2012 Byetta (exenatide) Injection and Bydureon (excenatide extended-release for injectable suspension). U.S. fact sheet
10. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, Seley JJ, Van den Berghe G 2012 Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 97:16-38
11. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403 (Pubitemid 34437694)
12. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 379:2243-2251
13. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S 2012 Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319-328
14. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F 2012 Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:1577-1585
15. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL 2012 Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366:1567-1576
16. Shah M, Simha V, Garg A 2006 Long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab 91:4223-4231 (Pubitemid 44833388)
17. Heber D, Greenway FL, Kaplan LM, Livingston E, Salvador J, Still C2010 Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 95:4823-4843
18. Inge TH, Krebs NF, Garcia VF, Skelton JA, Guice KS, Strauss RS, Albanese CT, Brandt ML, Hammer LD, Harmon CM, Kane TD, Klish WJ, Oldham KT, Rudolph CD, Helmrath MA, Donovan E, Daniels SR 2004 Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics 114:217-223 (Pubitemid 38857589)
19. Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F 2012 A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 366:2247-2256
20. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV 1986 Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes.NEngl J Med 315:215-219 (Pubitemid 16097122)
21. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS 2011 Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378:412-419
22. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry Jr RJ, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG 2011 Teplizumab for treatment of type 1 diabetes (Protégéstudy): 1-year results from a randomised, placebo-controlled trial. Lancet 378:487-497
23. Page KA, Seo D, Belfort-DeAguiar R, Lacadie C, Dzuira J, Naik S, Amarnath S, Constable RT, Sherwin RS, Sinha R 2011 Circulating glucose levels modulate neural control of desire for high-calorie foods in humans. J Clin Invest 121:4161-4169
24. Jastreboff AM, Sinha R, Lacadie C, Small DM, Sherwin RS, Potenza MN 15 October 2012 Neural correlates of stress- and food-cue-induced food craving in obesity: association with insulin levels. Diabetes Care 10.2337/dc12-1112
25. Stice E, Yokum S, Burger KS, Epstein LH, Small DM 2011 Youth at risk for obesity show greater activation of striatal and somatosensory regions to food. J Neurosci 31:4360-4366
26. Lin HV, Ren H, Samuel VT, Lee HY, Lu TY, Shulman GI, Accili D 2011 Diabetes in mice with selective impairment of insulin action in Glut4-expressing tissues. Diabetes 60:700-709
27. Paranjape SA, Chan O, Zhu W, Horblitt AM, Grillo CA, Wilson S, Reagan L, Sherwin RS 2011 Chronic reduction of insulin receptors in the ventromedial hypothalamus produces glucose intolerance and islet dysfunction in the absence of weight gain. Am J Physiol Endocrinol Metab 301:E978-E983
28. Anthony K, Reed LJ, Dunn JT, Bingham E, Hopkins D, Marsden PK, Amiel SA 2006 Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes 55:2986-2992 (Pubitemid 44923634)
29. Sandoval DA, Obici S, Seeley RJ 2009 Targeting the CNS to treat type 2 diabetes. Nat Rev Drug Discov 8:386-398
30. Committee for Medicinal Products for Human Use (CHMP) 2012 Summary of opinion (initial authorisation): Forxiga (dapagliflozin). London: European Medicines Agency
31. Nair S, Wilding JP 2010 Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 95:34-42
32. List JF, Woo V, Morales E, Tang W, Fiedorek FT 2009 Sodiumglucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32:650-657
33. Burki TK 2012 FDA rejects novel diabetes drug over safety fears. Lancet 379:507
34. Jones D 2011 Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 10:645-646
35. Leung K 2004 Ferumoxtran. Molecular Imaging and Contrast Agent Database (MICAD). 2004-2012. Bethesda, MD: National Center for Biotechnology Information. http://www.ncbi.nlm.nih.gov/books/NBK23402/ date accessed: September 16, 2012
36. Gaglia JL, Guimaraes AR, Harisinghani M, Turvey SE, Jackson R, Benoist C, Mathis D, Weissleder R 2011 Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest 121:442-445
37. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM 2012 A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463-468
38. Reynolds G 2012 Exercise hormone may fight obesity and diabetes. New York Times, January 11, 2012; http://well.blogs.nytimes.com/2012/01/11/exercise- hormone-helps-keep-us-healthy/
39. Puigserver P, Spiegelman BM 2003 Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator. Endocr Rev 24:78-90 (Pubitemid 36223280)